← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,859	-17	-0.4%	$266B
2	2 Merck MRK $358B	3,545	+106	+3%	$257B
3	3 AbbVie ABBV $501B	3,388	+60	+2%	$228B
4	4 Pfizer PFE $168B	2,883	-57	-2%	$106B
5	5 Amgen AMGN $235B	2,722	+5	+0.2%	$117B
6	6 Bristol-Myers Squibb BMY $124B	2,339	-27	-1%	$84.7B
7	7 Gilead Sciences GILD $195B	1,724	-55	-3%	$76.2B
8	8 Regeneron Pharmaceuticals REGN $82B	1,312	+39	+3%	$89.3B
9	9 Novartis NVS $286B	1,255	-17	-1%	$13.6B
10	10 AstraZeneca AZN $259B	1,143	+12	+1%	$33.8B
11	11 GSK GSK $98.2B	912	+16	+2%	$13.3B
12	12 DELISTED Exact Sciences EXAS	627	-20	-3%	$11.3B
13	13 Incyte INCY $23B	587	+30	+5%	$12.4B
14	14 Jazz Pharmaceuticals JAZZ $13.9B	481	-19	-4%	$6.97B
15	15 Exelixis EXEL $15.6B	422	-5	-1%	$6.02B
16	16 Halozyme HALO $13.8B	414	+4	+1%	$5.03B
17	17 Natera NTRA $58.3B	413	+62	+18%	$10.9B
18	18 Lantheus LNTH $6.53B	410	+9	+2%	$4.19B
19	19 Takeda Pharmaceutical TAK $62.1B	315	+8	+3%	$1.09B
20	20 BioNTech BNTX $22.7B	287	+6	+2%	$3.78B
21	21 Qiagen QGEN $9.53B	283	+5	+2%	$5.83B
22	22 DELISTED Blueprint Medicines BPMC	282	+23	+9%	$6.25B
23	23 Iovance Biotherapeutics IOVA $6.67B	273	+37	+16%	$3.22B
24	24 NeoGenomics NEO $2.22B	263	-24	-8%	$2.02B
25	25 Guardant Health GH $22.3B	258	-37	-13%	$2.3B